雷洛昔芬是激素吗？雷洛昔芬有什么副作用？

An estrogen receptor modulator that antagonizes estrogen in the uterus and breast tissue, inhibiting the proliferation of breast epithelium and endometrium. It exhibits an stimulant effect on psoriasis metabolism and has an estrogen-like effect. Raloxifene combined with calcium preparations can prevent bone loss, maintain bone density and lower blood lipids. Is it hormones? What are the side effects of raloxifene?

Indications for raloxifene

Raloxifene is a benthiophene compound, a new concept non-hormonal drug that resists bone resorption, and is a second-generation selective estrogen receptor modulator (SERM). Raloxifene is mainly used to prevent and treat osteoporosis in postmenopausal women. It can significantly reduce the incidence of vertebral fractures, but the reduction in the incidence of hip fractures has not been confirmed.

Common side effects of raloxifene include: vasodilation (hot flashes), venous thromboembolic events: including deep vein thrombosis, pulmonary embolism, retinal vein thrombosis, superficial vein thrombophlebitis, calf cramps, influenza symptoms, peripheral edema, thrombocytopenia, nausea, vomiting, abdominal pain, indigestion, rash, mild breast symptoms, etc. Patients should not use raloxifene blindly.

Raloxifene related clinical trials

In a study of 10,101 postmenopausal women with a history of coronary heart disease or an increased risk of coronary events (RUTH), the incidence of vasodilation (hot flashes) was 7.8% in the raloxifene group and 4.7% in the placebo group.

Venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis, occurred less frequently in all placebo-controlled clinical studies of raloxifene in osteoporosis. The relative risk of treatment with raloxifene compared with placebo was 1.60. The risk of venous thromboembolic events is greatest within 4 months of starting treatment. The incidence of superficial vein thrombophlebitis is less than 1%.

In the RUTH study, the frequency of venous thromboembolic events was approximately 2.0% or 3.88 events per 1,000 patient-years in the raloxifene-treated group and approximately 1.4% or 2.70 events per 1,000 patient-years in the placebo group. Superficial venous thromboembolism events in the RUTH study were 1% in the raloxifene group and 0.6% in the placebo group.

The above is the introduction about raloxifene, I hope it can help everyone.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: